Abstract

The effect of gender on the pharmacokinetics of rivastigmine (CAS 123441-03-2) was studied in male and female Wistar rats following intravenous bolus administration. The area under the plasma concentration-time curve (AUC), apparent volume of distribution (Vd), systemic clearance (CL), and terminal plasma half-life (t1/2) of rivastigmine were compared between male and female rats. Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h). The male rats had a 2.5 fold greater elimination rate constant than female rats (2.02 vs. 0.82 h-1). Gender had a significant effect on the pharmacokinetics of rivastigmine. Gender differences were reported due to gonadal hormones, and the observed difference in pharmacokinetics of rivastigmine might be attributed to testosterone in male rats.

Original languageEnglish
Pages (from-to)493-497
Number of pages5
JournalArzneimittel-Forschung/Drug Research
Volume59
Issue number10
Publication statusPublished - 2009

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Fingerprint Dive into the research topics of 'Gender differences in the pharmacokinetics of rivastigmine in rats'. Together they form a unique fingerprint.

  • Cite this